Powering The Markets: Trading & Data Giants
Major US indexes like the S&P 500 and Nasdaq are hitting record highs, signaling strong investor confidence. This creates a potential opportunity for companies that provide the essential infrastructure for market trading and data analysis, as they benefit from increased market activity.
Your Basket's Financial Footprint
Interpretation of market capitalisation breakdown for the basket 'Powering The Markets: Trading & Data Giants'. Includes concise summary and investor takeaways.
- Large cap dominance generally implies lower volatility and returns that track the broader market, not outsized swings.
- Treat this basket as a potential core holding for diversification, not a speculative, high-risk growth play.
- Expect steady, long-term capital appreciation rather than rapid, short-term gains; growth is likely more measured.
CME: $96.80B
ICE: $89.75B
NDAQ: $51.83B
- Other
About This Group of Stocks
Our Expert Thinking
With the S&P 500 and Nasdaq hitting record highs in July 2025, we're seeing unprecedented investor confidence and market activity. This creates a unique opportunity to invest in the companies that actually power these markets - the exchanges, trading platforms, and data providers that benefit directly from increased trading volumes and market participation.
What You Need to Know
These are the 'picks and shovels' companies of the financial world. They make money from transaction fees, data subscriptions, and clearing services that grow when markets are active. Unlike individual stocks that can be unpredictable, these infrastructure providers tend to benefit consistently from overall market growth and increased trading activity.
Why These Stocks
Each company in this group was handpicked by professional analysts for their essential role in market operations. From major exchanges like CME and Nasdaq to trading platforms and financial data firms, these stocks represent the backbone infrastructure that makes modern investing possible and profitable during market rallies.
Why You'll Want to Watch These Stocks
Record Market Momentum
With the S&P 500 and Nasdaq hitting 12 record highs in July alone, these infrastructure companies are positioned to benefit from the surge in trading activity and investor participation.
Essential Market Backbone
These companies provide the critical infrastructure that makes every trade possible. As market activity increases, their transaction fees, data subscriptions, and clearing services grow alongside it.
Picks and Shovels Strategy
Instead of betting on individual winners, you're investing in the companies that profit regardless of which stocks go up or down. They make money when the market is active, period.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Global Infrastructure Partners: UAE Exposure Risks
The UAE's strategic push for economic diversification and smart city development is creating significant demand for advanced construction and infrastructure solutions. This basket provides exposure to a selection of US and EU-listed companies that supply essential materials, technology, and engineering services to the region's projects.
UAE Infrastructure Global Suppliers Breakdown
As the UAE continues its ambitious economic diversification, demand for world-class infrastructure creates opportunities for the companies that build it. This basket offers exposure to US and EU-listed industrial, materials, and technology firms that are integral to developing these large-scale projects.
Antiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.